Drug-resistant mutations of hepatitis B virus (HBV) are the major obstacles to successful therapy for chronic hepatitis B infection. Although there are many methods for detecting the antiviral drug-resistant mutations of HBV, their applications are restricted because of their shortcomings, such as low sensitivity, the time required, and the high cost. For this study, a multiplex ligation-dependent probe real-time PCR (MLP-RT-PCR) method was developed to simultaneously detect lamivudine (LAM)and adefovir (ADV)-resistant HBV mutants (those with the mutations rtM204V/I, rtA181V/T, and rtN236T). The new method combined the high-throughput nature of multiplex ligation-dependent probe amplification (MLPA) with the rapid and sensitive detection of real-time PCR. In this report, MLP-RT-PCR was evaluated by detecting drug-resistant mutants in 116 patients with chronic hepatitis B infection. By MLP-RT-PCR analysis, LAM-resistant mutations were detected in 41 patients (35.3%), ADVresistant mutations were detected in 17 patients (14.7%), and LAM-and-ADV-resistant mutations were detected in 5 patients (4.3%). Based on the results of MLP-RT-PCR, the mutations rtM204V, rtM204I, rtA181T, rtA181V, and rtN236T were 95.7% (111/116 patients), 98.3% (114/116 patients), 99.1% (115/116 patients), 98.3% (114/116 patients), and 99.1% (115/116 patients) concordant, respectively, with those of direct sequencing. The MLP-RT-PCR assay was more sensitive than direct sequencing for detecting mutations with low frequencies. Four samples containing the low-frequency (<10%) mutants were identified by MLP-RT-PCR and further confirmed by clonal sequencing. MLP-RT-PCR is a rapid and sensitive method that enables the detection of multidrug-resistant HBV mutations in clinical practice.
C hronic hepatitis B virus (HBV) infection remains a major public health problem worldwide. Two drugs, lamivudine (LAM) and adefovir (ADV), are presently used as first-line therapies against HBV in China. Antiviral drug resistance is the major obstacle to successful long-term therapy for chronic hepatitis B infection (1, 2) . The detection of mutations associated with resistance to LAM and ADV is very important for the clinical selection of drugs used against HBV. At present, there are many methods to detect drug-resistant mutations of HBV, including direct sequencing from PCR products, reverse hybridization INNO-LiPA, microarray, and real-time PCR. Direct sequencing and INNO-LiPA are well-known methods used in clinical practice. Although direct sequencing is the gold standard for the detection of mutations, it cannot detect mutations that are present at a low frequency (Ͻ20%) in the viral population (3) . The INNO-LiPA (4, 5) is more sensitive, but the reagents and equipment are costly. Microarray is high-throughput but is also costly; therefore, a microarray cannot be widely used in clinical practice (6) . With the development of new technologies in molecular diagnostics, realtime PCR was applied to detect HBV mutations. For many realtime PCRs, the mutants and wild-type strains were distinguished by changes in the melting temperatures (T m ) of the fluorescence probes (7) , which result in a low rate of identification of mutations with similar T m values, adjacent mutations, and silent mutations. Moreover, the mutation sites need to be located in the middle of the fluorescence probes, such as in a type-specific minor groove binder probe (8) (9) (10) or a locked nucleic acid probe (11) , thus restricting the design of probes and the detection flux. In most cases, only single-codon mutations can be detected by traditional real-time PCR. We have developed a new detection method, multiplex ligation-dependent real-time PCR (MLP-RT-PCR), which combines multiplex ligation-dependent probe amplification (MLPA) with real-time PCR. The method can be applied to quickly detect five HBV mutations associated with resistance to LAM and ADV in one tube, including the mutations rtM204V/I, rtA181V/T, and rtN236T in the reverse transcriptase domain of the HBV P gene (12) (13) (14) . Schouten et al. (15) reported on the first MLPA assay in 2002. Forty pairs of MLPA probes were designed to detect changes in gene copies. The assay can also be used to detect single nucleotide polymorphism (SNPs) and point mutations (16) , and it has been applied for detecting multiple-drug-resistant mutations and genotyping in Mycobacterium tuberculosis (17, 18) . In the traditional MLPA, pathogens are quantified and genotyped by capillary electrophoresis (18) or microarray (17) . The synthesis of many different lengths of MLPA probes or complex operations, such as the fixation of probes, hybridization, and elution, are needed. However, using a TaqMan probe inserted into the MLPA probe as a tag, the MLPA probe can be directly amplified by realtime PCR and the results can be directly analyzed without capil-lary electrophoresis or microarray. Here, for the first time, MLPA combined with real-time PCR was used to detect point mutations and drug-resistant mutations in HBV. Fig.  1 . Each MLPA probe consists of two short synthetic oligonucleotides named the 5= probe and the 3= probe. The 3= probe was phosphorylated at the 5= end. Each short probe contained a sequence as a common primer for PCR and a sequence for hybridization. At least one short probe contained a specific sequence as a tag (a TaqMan probe was used in this report) between the primer sequence and the hybridization sequence. When two short probes hybridized to the target sequences under the appropriate conditions, the 3= end of the 5= probe was adjacent to the 5= end of the 3= probe. A complete single MLPA probe was obtained when the two probes were ligated by DNA ligase enzyme. To ensure ligation, the 3= end of the 5= probe had to be perfectly paired with the target sequence. The ligation products were then amplified by real-time PCR using a pair of common primers and a TaqMan probe ( Fig. 1) .
MATERIALS AND METHODS

MLP-RT-PCR. An outline of the MLP-RT-PCR reaction is shown in
Design of universal primers, TaqMan probes, and MLPA probes. A pair of common primers for the chloroplast genome in Medicago sativa was designed using Primer Premier 6.00. Five TaqMan probes were designed using Primer Express 3.0 and labeled individually with 6-carboxyfluorescein (FAM), HEX, ROX, Cy5, and LightCycler (LC) Red 705 (Sangon Biotech, Shanghai, China). The T m of the TaqMan probe was 10°C higher than that of the primer; the probes were unlikely to form selfdimers, hairpin structures, or cross-dimers. The MLPA probes were designed as previously reported, with modifications (15) . First, the sequences of the HBV P gene were searched against the NCBI nucleotide database, and multiple sequence alignments were made using Clustal X 1.83. Next, according to the sequences from HBV genotypes B and C, which are the most prevalent in China, MLPA probes were designed for detecting the rtM204V/I, rtA181V/T, and rtN236T mutations. The T m of the hybridization sequence was Ͼ65°C and the mutation site was located at the 3= end of the 5= probe. To improve the specificity of detection, one mismatched base was designed in the second-to-last base at the 5= end of the 3= probe for the rtM204V and rtM204I mutations and one mismatch base in the third-to-last base at the 3= end of the 5= probe for the rtA181T and rtA181V mutations. All probes were synthesized and then purified by high-performance liquid chromatography (Sangon Biotech) ( Table 1) .
Blood serum samples. One hundred sixteen blood serum samples that were positive for HBV were collected from outpatients and inpatients at the Department of Infectious Disease at Southwest Hospital in the Third Military Medical University (Chongqing, China) between March 2012 and June 2013. All patients had received anti-HBV nucleos(t)ide analogue monotherapy, combination therapy, or sequential therapy for a minimum of 3 months. The study was approved by the ethics committee of the hospital.
DNA extraction and PCR amplification before detection. HBV DNA was extracted from 100 l of blood serum using an HBV quantitative PCR (qPCR) assay kit (Qiagen, Germany), according to the manufacturer's instructions. The reverse transcriptase fragment (300 bp) of the HBV P gene covering all mutations was amplified using a PrimeSTAR Max DNA polymerase kit (TaKaRa, Japan) with the sense primer 5=-CCCCAACTC CCAATTACATATCC-3= and the antisense primer 5=-CCCATCATCTT GGGCTTTCG-3=. The PCR conditions were 35 cycles at 98°C for 10 s, 55°C for 5 s, and 72°C for 30 s.
MLP-RT-PCR assay. The reverse transcriptase fragment products of the HBV P gene were first diluted with distilled water to 4 ng/l. The diluted samples (0.5 l) were then transferred to 200-l tubes. After the addition of a 1-l salt solution (1.5 M KCl, 300 mM Tris-HCl [pH 8.5], 1 mM EDTA) (15) , the samples were blended with a 0.5-l mixture of five MLPA probes (50 to 500 pM of each probe), and distilled water was added for a final volume of 5 l. The samples were heated at 95°C for 5 min and then incubated at 60°C for 1 h (19) . Ligation was performed by diluting the samples to 10 l with dilution buffer (20 mM Tris-HCl, 25 mM KAc, 10 mM Mg(Ac) 2 , 10 mM dithiothreitol [DTT], 1 mM NAD, 0.1% Triton X-100 [pH 7.6]) containing 1,000 U/ml Taq DNA ligase (NEB, USA). The samples were incubated at 60°C for 20 min and then heated at 98°C for 5 min to inactivate the ligase enzyme. TaqMan real-time PCR was performed in a total volume of 25 l with a Premix Ex Taq kit (product no. DRR390A; TaKaRa) containing mix buffer (12.5 l), ligation products (5 l), universal primers (0.2 M), TaqMan probes (120 nM) labeled with FAM, HEX, ROX, and Cy5, and TaqMan probe (84 nM) labeled with LC-Red 705. The real-time PCR was performed with the denaturation at 95°C for 30 s, followed by 45 cycles of denaturation at 95°C for 5 s and annealing at 55°C for 30 s. The fluorescence signal was detected at the end of the annealing step in a Rotor-GeneQ (Qiagen, Germany).
Direct sequencing. The reverse transcriptase fragment of the HBV P gene was amplified by nested PCR before sequencing. The first-round amplification was performed using the outer primers F-out-5=-TCCTGC TCAAGGAACCTCTA-3= and R-out-5=-AGGCCTTATAAGTTGGCGA-3=. The first round of PCR was performed as follows: 94°C for 8 min, followed by 30 cycles of 94°C for 30 s, 54°C for 30 s, and 72°C for 1 min, and a final extension at 72°C for 10 min. With the products as the template, the second amplification was conducted using the inner primers F-in-5=-CY(T/C)TGTATTCCCATCCCATC-3= and R-in-5=-TGACATA CTTTCC AATCAATAGG-3=. Conditions for the second round of PCR were 94°C for 8 min, followed by 30 cycles at 94°C for 30 s, 55°C for 40 s, and 72°C for 50 s and a final extension at 72°C for 10 min. The PCR products were purified and then subjected to sequencing (Beijing Genomics Institute, China).
Construction of negative and positive controls. The reverse transcriptase fragment of the HBV P gene was amplified by general PCR as described in "DNA extraction and PCR amplification before detection," above. The PCR products were purified and then ligated into the pMD18-T vector (TaKaRa). The plasmids containing the wild fragments confirmed by clonal sequencing were used as the negative controls (wild strains). Five positive mutation controls were obtained using the same procedures.
Clonal sequencing. A clonal analysis of the reverse transcriptase fragment of the HBV P gene was performed as previously reported after the MLP-RT-PCR assay (20) . In brief, the reverse transcriptase fragment of the HBV P gene was amplified by general PCR as described in "DNA extraction and PCR amplification before detection," above. The PCR products were purified and ligated into the pUC57 vector (Sangon Biotech). The colonies were first screened by colony PCR, and then at least 20 positive colonies were chosen to be sequenced (Sangon Biotech).
Statistical analysis. The data were analyzed using SPSS (version 13.0). The chi-square test and McNemar's test were used to compare the sensitivities (the mutation detection rates) of MLP-RT-PCR and direct sequencing. The consistency between the two methods was calculated using the Kappa test.
RESULTS
Performance of MLP-RT-PCR.
The MLPA procedures were optimized by changing the conditions of hybridization and ligation (see the supplemental material). We found that hybridization at a constant temperature (60°C) yielded better results than heating and cooling. The ligation efficiency of Taq DNA ligase (NEB, USA) was greater than that of ligase-65 (MRC-Holland, Holland, the Netherlands).
In order to optimize the specificities of the MLPA probes for detecting point mutations, four kinds of MLPA probes were designed to evaluate the specificity of MLP-RT-PCR. The probes shown in Table 1 were finally chosen to detect clinical samples. There was no cross-reaction among the five mutations and the five pairs of MLPA probes (see the supplemental material).
To evaluate the sensitivity of MLP-RT-PCR, we found that the amplification efficiency of real-time PCR for each mutation was very high (99% to 105%). To better evaluate the MLP-RT-PCR method for detecting low-frequency mutations, synthesized sequences with mutations were mixed with wild sequences in different ratios totaling 1.5 ϫ 10 9 copies. We found that the sequences with the mutations rtM204V, rtM204I, rtA181T, and rtN236T, whose frequencies were Ͼ0.1%, were detected by MLP-RT-PCR; sequences with the mutation rtA181V, whose frequency was Ͼ1%, were detected by MLP-RT-PCR (see the supplemental material). Clinical sample detection and statistical analysis. MLP-RT-PCR and direct sequencing were used to analyze the samples from 116 patients with chronic hepatitis B infection. MLP-RT-PCR was conducted twice for each sample. A comparison of the positive rates of detection by MLP-RT-PCR and direct sequencing is summarized in Table 2 . The results of the chi-square test indicated that there was no significant difference between the two methods (P Ͼ 0.05). The concordance between the two methods is shown in Table 3 . For the rtM204V mutation, five additional samples, which were not detected using direct sequencing, were detected with MLP-RT-PCR. The kappa value of 0.715 indicated a high concordance between the two methods. For the rtM204I mutation, one sample was labeled negative using direct sequencing but labeled positive using MLP-RT-PCR. Another sample was labeled negative by MLP-RT-PCR because of the preamplification failure before the detection step, although the sample was labeled positive by direct sequencing. The kappa value of 0.962 indicated excellent concordance between the two methods. For the rtA181T mutation, there was one sample with a mutation that was not detected using MLP-RT-PCR. The kappa value of 0.905 indicated excellent concordance between the two methods. For the rtA181V mutation, one sample with a mutation confirmed by direct sequencing was not detected by MLP-RT-PCR because of the low virus load in the sample (no products were preamplified). Another sample was labeled negative using direct sequencing but labeled positive using MLP-RT-PCR. The kappa value of 0.880 indicated a high concordance between the two methods. One sample was labeled positive for the rtN236T mutation using direct sequencing, while it was labeled negative using MLP-RT-PCR. The kappa value of 0.965 indicated an excellent concordance between the two methods for the rtN236T mutation. The frequencies of the various mutations at the 3-codon position by MLP-RT-PCR are summarized in Table 4 . Of 116 samples, LAM-resistant mutations were detected in 41 patients (35.3%), ADV-resistant mutations were detected in 17 patients (14.7%), and LAM-and-ADV-resistant mutations were detected in 5 patients (4.3%).
Clonal sequencing. To further validate the accuracy of MLP-RT-PCR, six samples, the results of which were not concordant with those of direct sequencing, were chosen for clonal sequencing. At least 20 colonies from each sample were randomly chosen for sequencing. Four samples were found to contain the low-frequency mutants ( Table 5 ), suggesting that MLP-RT-PCR had a higher capability than direct sequencing to detect mutants with multiple mutations and in low proportions.
DISCUSSION
Here, we developed a new method to detect the usual drug-resistant mutations of HBV. This method can simultaneously detect five mutations in one tube. The entire assay can be completed in 4 to 5 h.
To avoid false-negative and false-positive results, a positive control and negative control were used in the experiments. Furthermore, mismatches were taken into account in designing the MLPA probes. After many trials, a mismatched base was added at the second-to-last base in the 5= end of the 3=-MLPA probe for the mutations rtTM204V and rtM204I, which helped to avoid crossreactions between the two probes and improve the specificity of the method (see the supplemental material). Moreover, a G/T mismatch may occur when detecting the rtA181T mutation, so one mismatched base was added at the third-to-last base in the 3= end of the 5= probes for the mutations rtA181T and rtA181V, which helped to avoid cross-reactions between the two probes as well as the false-positive result caused by the G/T mismatch (see the supplemental material). However, the sensitivity might be impaired by the addition of mismatches. In one sample that contained both the rtA181T and rtA181V mutations, the adjacent mutated bases and the mismatched base might have resulted in unstable binding of MLPA probes to their targets, decreasing the sensitivity of MLP-RT-PCR. Therefore, only the rtA181V mutation was detected by MLP-RT-PCR in one sample that contained both rtA181T and rtA181V mutations, as confirmed by direct sequencing. On the contrary, there was little influence when one sample contained both the rtM204V and rtM204I mutations because the two mutated bases are not adjacent. All samples with both rtM204V and rtM204I as confirmed by direct sequencing were detected by MLP-RT-PCR. SNPs near a mutation site may also affect the sensitivity of MLP-RT-PCR. The MLPA probes and primers used in the MLP-RT-PCR were designed according to genotypes B and C of HBV, which are the most prevalent (94%) genotypes in China (21) . The HBV P-gene fragments of genotypes A, B, C, and D, which were found in China (21) , were aligned (data not shown). We found that the MLPA probes for each mutation effectively hybridized to the target sequences of genotypes A to D, but this was not very stable when the antisense primer for general PCR bound to the target sequences of genotypes A and D. Therefore, the detection rates of genotypes A and D in our study may have been decreased.
The nested PCR primers were also aligned with the HBV P-gene fragments of genotypes A to D (data not shown). We found that all primers can effectively bind to the target sequences of genotypes A to D. Therefore, the reverse transcriptase fragment of the HBV P gene of genotypes A to D can be preamplified by nested PCR. However, genotypes A and D were not discovered in the 116 patients in our study.
Besides the design of MLPA probes and primers, the sensitivity of MLP-RT-PCR was also affected by the ligation efficiency. The ligation efficiency of the MLPA probes can be influenced by hybridization time, hybridization conditions, and the activity of the ligase enzyme. To shorten the detection time and simplify the procedure, hybridization for 1 h at a constant temperature was chosen as the proper set of conditions and the ligation efficiencies were compared between TaqDNA ligase and ligase-65. The ligation efficiency of the TaqDNA ligase was greater than that of ligase-65 (see the supplemental material). Besides the ligation efficiency, the amplification efficiency of real-time PCR also affected the sensitivity of the MLP-RT-PCR. The real-time PCR was performed using a pair of common primers for the ligated MLPA probe with about 120 bp, which unified the reaction conditions for the detection of these five mutations. In some detection channels, mutations can be detected even when the percentage is as low as 0.1% (see supplemental material). Some mutations in clinical samples that were not detected by direct sequencing were detected LAM  rtM204V  3  2  1  rtM204I  33  17  16  rtM204V/I  5  5  0  ADV  rtA181V  3  1  2  rtA181T  2  2  0  rtA181V  rtN236T  6  6  0  rtA181T  rtN236T  2  2  0  rtN236T (20/22, 91) using MLP-RT-PCR, especially for the rtM204V mutation, as shown in Table 4 (footnote a), including three samples with rtM204V and rtN236T mutations and one sample with rtM204V/I and rtN236T mutations. These mutations were associated with both LAM resistance and ADV resistance and were rarely detected before (22) even though they existed. Using highly sensitive direct PCR sequencing, Liu and colleagues (20) also detected these mutations in the HBV patients who received LAM with add-on ADV treatment or received LAM and then switched to ADV. We found that patients with these HBV mutants had received LAM plus ADV combination therapy for at least 2 years in district hospitals. They came to Southwest Hospital due to the recurrence of hepatitis B. Clonal sequencing also showed that two samples had simultaneous rtM204V and rtN236T mutations, one sample was found to have the rtM204I and rtN236T mutations, and one sample was found to have the rtA181V and rtN236T mutations ( Table  5 ). The frequencies of the additional mutations found by MLP-RT-PCR were Ͻ10%. These results indicated that MLP-RT-PCR had a higher sensitivity than direct sequencing for detecting mutations present in low proportions.
In addition, the cost of reagents and equipment used in MLP-RT-PCR is much less than that for direct sequencing. The cost of the reagents used for one sample in MLP-RT-PCR is estimated to be $3.00. The equipment required for MLP-RT-PCR includes a real-time PCR instrument with five fluorescence channels, a general PCR instrument, a high-speed centrifuge, and a super-clean worktable. Most of this equipment is available in molecular biology laboratories. A skilled technician who can perform PCR techniques can complete the whole procedure of MLP-RT-PCR assay smoothly.
However, MLP-RT-PCR has some disadvantages. The amplification sensitivity (Ͻ3,000 IU/ml) of general PCR used in MLP-RT-PCR is much less than that of the nested PCR (limit of detection [LOD], 500 IU/ml) used in the direct sequencing. Therefore, two samples were not identified using MLP-RT-PCR. To improve the detection rates in future research, more sensitive PCR and optimal conditions need to be applied to MLP-RT-PCR. Another disadvantage of MLP-RT-PCR is that there is no linear relationship between the mutant viral load and quantification cycle (C q ) value. Therefore, it is difficult to quantify the mutation strains as well as acquire a definite ratio of mutation strains to wild strains. In addition, if MLP-RT-PCR is applied to the molecular diagnosis of other pathogens, only known mutations can be detected and the SNPs located near the expected mutation sites may affect the sensitivity of the method.
Although it has some limitations, MLP-RT-PCR may be used to detect typical drug-resistant mutations of HBV in clinical practice because the detection results are highly concordant with those of direct sequencing. Moreover, with the advantages of easy operation, low cost, and short time requirements, MLP-RT-PCR can feasibly be used in clinical practice.
